{"id":27760,"date":"2022-06-17T10:06:32","date_gmt":"2022-06-17T17:06:32","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/uncategorized\/cidp-treatment-2\/"},"modified":"2026-04-16T15:02:48","modified_gmt":"2026-04-16T22:02:48","slug":"cidp-treatment","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-treatment\/","title":{"rendered":"Su gu\u00eda sobre tratamientos actuales y emergentes para la CIDP"},"content":{"rendered":"<ul class=\"wp-block-list\">\n<li>La IgIV, los corticosteroides y la plasmaf\u00e9resis son los tratamientos est\u00e1ndar actuales para la CIDP que controlan eficazmente los s\u00edntomas y reducen la inflamaci\u00f3n.<\/li>\n\n\n\n<li>Las terapias emergentes como Vyvgart Hytrulo se muestran prometedoras, especialmente para aquellos que no responden a los medicamentos tradicionales para la CIDP.<\/li>\n\n\n\n<li>No existe una cura definitiva. El tratamiento continuo es esencial para el control de los s\u00edntomas y la remisi\u00f3n de la enfermedad.<\/li>\n<\/ul>\n\n\n\n<p><a href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/what-is-cidp\/\">Polineuropat\u00eda desmielinizante inflamatoria cr\u00f3nica (PDIC)<\/a> Es un trastorno autoinmune poco com\u00fan que afecta aproximadamente a entre 5 y 7 personas por cada 100\u00a0000 en todo el mundo. Si bien puede provocar da\u00f1o nervioso progresivo y discapacidad, existen varias terapias que pueden ayudar a controlar los s\u00edntomas, reducir la inflamaci\u00f3n y ralentizar la progresi\u00f3n de la enfermedad.<\/p>\n\n\n\n<p>Mantenerse informado sobre los tratamientos disponibles y emergentes puede ayudar a los pacientes y a sus cuidadores a tomar mejores decisiones sobre el manejo de esta afecci\u00f3n.<\/p>\n\n\n\n<p>En esta gu\u00eda, revisaremos los medicamentos est\u00e1ndar actuales para la PDIC que se recetan a la mayor\u00eda de los pacientes. Tambi\u00e9n exploraremos tratamientos emergentes y analizaremos si existe una cura para la PDIC.<\/p>\n\n\n\n<p>Contin\u00fae leyendo para ver qu\u00e9 les depara el futuro a quienes son diagnosticados con esta enfermedad. <a href=\"https:\/\/ameripharmaspecialty.com\/es\/conditions-treatments\/auto-immune-conditions-treated-with-biologics\/\">enfermedad autoinmune<\/a>.<\/p>\n\n\n\n<div  id=\"call-to-action-150d97e90c62e467ca8e74a6cccc7c8b\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga autorizaci\u00f3n previa para IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:(877) 778-0318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-treatment\/#Standard_CIDP_Treatments\" >Tratamientos est\u00e1ndar de CIDP<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-treatment\/#Intravenous_Immunoglobulin\" >Inmunoglobulina intravenosa<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-treatment\/#Corticosteroids\" >Corticosteroides<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-treatment\/#Plasmapheresis\" >Plasmaf\u00e9resis<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-treatment\/#New_CIDP_Treatments\" >Nuevos tratamientos para la CIDP<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-treatment\/#Vyvgart_Hytrulo\" >Vyvgart Hytrulo<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-treatment\/#Other_Novel_CIDP_Treatments_Under_Investigation\" >Otros tratamientos novedosos para la CIDP en investigaci\u00f3n<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-treatment\/#Is_There_a_Cure_for_CIDP_Disease\" >\u00bfExiste una cura para la enfermedad CIDP?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-treatment\/#Manage_CIDP_With_AmeriPharma%C2%AE_Specialty\" >Administre CIDP con la especialidad AmeriPharma\u00ae<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\" id=\"h-standard-cidp-treatments\"><span class=\"ez-toc-section\" id=\"Standard_CIDP_Treatments\"><\/span>Tratamientos est\u00e1ndar de CIDP<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>En la actualidad, los m\u00e9dicos prescriben varios tratamientos est\u00e1ndar para personas con diferentes <a href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/living-with-cidp\/\">Etapas de la PDIC<\/a>. Estos tratamientos han demostrado ser eficaces para ayudar a los pacientes a controlar sus s\u00edntomas. A continuaci\u00f3n se presentan los tratamientos m\u00e1s com\u00fanmente recetados para el manejo de la CIDP.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-intravenous-immunoglobulin\"><span class=\"ez-toc-section\" id=\"Intravenous_Immunoglobulin\"><\/span>Inmunoglobulina intravenosa<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Inmunoglobulina intravenosa (<a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig\/\">IgIV<\/a>) es la principal opci\u00f3n terap\u00e9utica para la PDIC. No es un tratamiento nuevo, ya que se ha utilizado ampliamente durante m\u00e1s de dos d\u00e9cadas.<\/p>\n\n\n\n<p>Se trata de infundir anticuerpos derivados de donantes sanos en el torrente sangu\u00edneo de los individuos afectados para ayudar a modular la respuesta inmunitaria. <a href=\"https:\/\/ameripharmaspecialty.com\/es\/other-health-conditions\/ivig-for-cidp\/\">IgIV para la PDIC<\/a> Act\u00faa neutralizando los anticuerpos da\u00f1inos y reduciendo la inflamaci\u00f3n que da\u00f1a las vainas de mielina, una capa protectora alrededor de los nervios.<\/p>\n\n\n\n<p>El t\u00edpico <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7982536\/\" target=\"_blank\" rel=\"noreferrer noopener\">R\u00e9gimen de tratamiento de PDIC con IGIV<\/a> incluye:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Infusiones cada 3 a 4 semanas<\/li>\n\n\n\n<li>Dosis de carga inicial de 2 g\/kg durante 2 a 5 d\u00edas<\/li>\n\n\n\n<li>Dosis de mantenimiento de aproximadamente 1 g\/kg seg\u00fan sea necesario.<\/li>\n\n\n\n<li>Las mejoras del paciente se pueden ver en tan solo 2 semanas.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-side-effects-of-ivig-therapy\">Efectos secundarios de la terapia con IgIV<\/h4>\n\n\n\n<p>Si bien la mayor\u00eda de las personas generalmente toleran bien la IgIV, algunas pueden experimentar <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-common-side-effects-of-ivig-treatment\/\">efectos secundarios<\/a> como:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Fatiga<\/li>\n\n\n\n<li>Dolor de cabeza<\/li>\n\n\n\n<li>Fiebre o escalofr\u00edos<\/li>\n\n\n\n<li>N\u00e1useas o v\u00f3mitos<\/li>\n\n\n\n<li>En raras ocasiones, co\u00e1gulos de sangre o problemas renales.<\/li>\n\n\n\n<li>Reacciones al\u00e9rgicas, como sarpullido o <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-and-hypotension-when-low-blood-pressure-can-be-dangerous\/\">hipotensi\u00f3n<\/a><\/li>\n<\/ul>\n\n\n\n<p>Es fundamental que hable con su m\u00e9dico sobre la posibilidad de estas reacciones adversas para garantizar el uso seguro de este tratamiento eficaz contra la polineuropat\u00eda desmielinizante inflamatoria cr\u00f3nica (CIDP). Si se producen reacciones al\u00e9rgicas o intolerancia a la inmunoglobulina intravenosa (IVIG), su m\u00e9dico podr\u00eda recomendarle opciones de tratamiento alternativas.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-corticosteroids\"><span class=\"ez-toc-section\" id=\"Corticosteroids\"><\/span>Corticosteroides<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Los corticosteroides, como la prednisona, se encuentran entre las terapias m\u00e1s consolidadas para suprimir la respuesta inmunitaria anormal en la polineuropat\u00eda desmielinizante inflamatoria cr\u00f3nica (CIDP). Act\u00faan suprimiendo la actividad inmunitaria, reduciendo la inflamaci\u00f3n alrededor de los nervios y previniendo una mayor desmielinizaci\u00f3n.<\/p>\n\n\n\n<p>Los estudios demuestran que el 60% de los pacientes que reciben corticosteroides responde bien al tratamiento e incluso alcanza una remisi\u00f3n a largo plazo. Estos resultados convierten a los corticosteroides en una terapia de primera l\u00ednea eficaz, especialmente en casos donde se desea una r\u00e1pida supresi\u00f3n inmunitaria.<\/p>\n\n\n\n<p>Los corticosteroides pueden administrarse por v\u00eda oral diariamente o mediante infusiones mensuales. La dosis inicial y la decreciente depender\u00e1n de la situaci\u00f3n de cada individuo. <a href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-101-what-you-need-to-know-about-this-rare-disease\/\">S\u00edntomas de la PDIC<\/a> y la gravedad de la enfermedad.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-side-effects-of-corticosteroids\">Efectos secundarios de los corticosteroides<\/h4>\n\n\n\n<p>Aunque los corticosteroides son uno de los tratamientos m\u00e1s eficaces para la PDIC, pueden causar efectos secundarios significativos, especialmente con el uso prolongado. Los pacientes deben ser conscientes de riesgos como:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/ameripharmaspecialty.com\/es\/conditions-treatments\/osteoporosis\/\">Osteoporosis<\/a><\/li>\n\n\n\n<li>Cataratas o glaucoma<\/li>\n\n\n\n<li>Presi\u00f3n arterial elevada<\/li>\n\n\n\n<li>Mayor riesgo de infecciones<\/li>\n\n\n\n<li>Cambios de humor e irritabilidad<\/li>\n\n\n\n<li>Aumento de peso y retenci\u00f3n de l\u00edquidos<\/li>\n\n\n\n<li>Aumento de los niveles de az\u00facar en sangre o diabetes<\/li>\n<\/ul>\n\n\n\n<p>Estos riesgos potenciales ponen de manifiesto la necesidad de terapias m\u00e1s novedosas que puedan proporcionar un control eficaz de la enfermedad con menos efectos secundarios a largo plazo.<\/p>\n\n\n\n<div  id=\"call-to-action-4df78d2e4aa8529991592c5bb4f6cebf\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga asistencia para el copago de IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tHabla con un especialista\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-treatment\/#form\">Programar una consulta<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-plasmapheresis\"><span class=\"ez-toc-section\" id=\"Plasmapheresis\"><\/span>Plasmaf\u00e9resis<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-vs-plasmapheresis\/\">Plasmaf\u00e9resis<\/a> El intercambio de plasma es un procedimiento que consiste en extraer el plasma sangu\u00edneo del propio paciente, que contiene anticuerpos da\u00f1inos, y reemplazarlo con un l\u00edquido plasm\u00e1tico sustituto. Los anticuerpos son prote\u00ednas producidas por el organismo durante una respuesta inmunitaria.<\/p>\n\n\n\n<p>Este tratamiento para la CIDP reduce eficazmente los anticuerpos pat\u00f3genos circulantes que atacan los nervios en pacientes con CIDP. Es especialmente \u00fatil en casos agudos o refractarios donde se requiere un control r\u00e1pido de la enfermedad.<\/p>\n\n\n\n<p><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6734114\/\" target=\"_blank\" rel=\"noreferrer noopener\">Estudios<\/a> La plasmaf\u00e9resis puede ser una terapia adyuvante eficaz con importantes beneficios a corto plazo para los pacientes con PDIC. Un esquema de tratamiento t\u00edpico para este procedimiento incluye:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Generalmente de 5 a 10 sesiones durante 2 a 4 semanas.<\/li>\n\n\n\n<li>Las sesiones normalmente se realizan cada dos d\u00edas o semanalmente.<\/li>\n\n\n\n<li>Cada sesi\u00f3n intercambia aproximadamente entre 1 y 1,5 vol\u00famenes de plasma.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-side-effects-of-plasmapheresis\">Efectos secundarios de la plasmaf\u00e9resis<\/h4>\n\n\n\n<p>Aunque generalmente es seguro, al igual que otros medicamentos para la PDIC, la plasmaf\u00e9resis conlleva riesgos potenciales. Algunos de los efectos secundarios m\u00e1s comunes de este tratamiento para la PDIC incluyen:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Riesgo de infecciones<\/li>\n\n\n\n<li>Sangrado o hematomas en los sitios de inserci\u00f3n<\/li>\n\n\n\n<li>Reacciones al\u00e9rgicas al sustituto de plasma<\/li>\n\n\n\n<li>Desequilibrios electrol\u00edticos, como la hipocalcemia<\/li>\n\n\n\n<li>Hipotensi\u00f3n o mareos durante o despu\u00e9s de las sesiones.<\/li>\n<\/ul>\n\n\n\n<p>Como tratamiento eficaz, la plasmaf\u00e9resis ofrece un alivio r\u00e1pido de los s\u00edntomas, pero requiere un seguimiento cuidadoso para minimizar los riesgos. Esta es otra raz\u00f3n por la que encontrar un tratamiento menos riesgoso para curar la PDIC deber\u00eda ser una prioridad.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-new-cidp-treatments\"><span class=\"ez-toc-section\" id=\"New_CIDP_Treatments\"><\/span>Nuevos tratamientos para la CIDP<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/06\/cidp-medications-man-pills-1024x683-1.jpg\" alt=\"An old man taking medications\" class=\"wp-image-27762\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/06\/cidp-medications-man-pills-1024x683-1.jpg 1024w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/06\/cidp-medications-man-pills-1024x683-1-300x200.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/06\/cidp-medications-man-pills-1024x683-1-768x512.jpg 768w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/06\/cidp-medications-man-pills-1024x683-1-18x12.jpg 18w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/06\/cidp-medications-man-pills-1024x683-1-600x400.jpg 600w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/06\/cidp-medications-man-pills-1024x683-1-330x220.jpg 330w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/06\/cidp-medications-man-pills-1024x683-1-86x57.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/06\/cidp-medications-man-pills-1024x683-1-167x111.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/06\/cidp-medications-man-pills-1024x683-1-280x187.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/06\/cidp-medications-man-pills-1024x683-1-370x247.jpg 370w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2022\/06\/cidp-medications-man-pills-1024x683-1-960x640.jpg 960w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Los avances recientes est\u00e1n revelando nuevas opciones para el manejo de la PDIC. A continuaci\u00f3n, se presentan algunos de los tratamientos emergentes m\u00e1s prometedores para la PDIC.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-vyvgart-hytrulo\"><span class=\"ez-toc-section\" id=\"Vyvgart_Hytrulo\"><\/span>Vyvgart Hytrulo<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Vyvgart Hytrulo fue <a href=\"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-chronic-inflammatory-demyelinating-polyneuropathy-cidp-adults\" target=\"_blank\" rel=\"noreferrer noopener\">Aprobado por la FDA en 2024<\/a>, espec\u00edficamente para la CIDP en adultos. Este medicamento para la CIDP combina efgartigimod alfa, un bloqueador del receptor Fc (FcRn) neonatal, con hialuronidasa para mejorar la absorci\u00f3n del f\u00e1rmaco.<\/p>\n\n\n\n<p>Efgartigimod alfa act\u00faa reduciendo los autoanticuerpos IgG pat\u00f3genos responsables de la inflamaci\u00f3n nerviosa.<\/p>\n\n\n\n<p>Los datos de los ensayos cl\u00ednicos han demostrado resultados prometedores. En el ensayo cl\u00ednico ADHERE, los pacientes que recibieron Vyvgart Hytrulo tuvieron una probabilidad significativamente menor de experimentar una reca\u00edda de la enfermedad o un empeoramiento de los s\u00edntomas en comparaci\u00f3n con aquellos que recibieron un placebo.<\/p>\n\n\n\n<p>Vyvgart Hytrulo puede ser un nuevo tratamiento prometedor para la CIDP, especialmente en aquellos que no responden bien a las terapias tradicionales como la IgIV y la plasmaf\u00e9resis.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-other-novel-cidp-treatments-under-investigation\"><span class=\"ez-toc-section\" id=\"Other_Novel_CIDP_Treatments_Under_Investigation\"><\/span>Otros tratamientos novedosos para la CIDP en investigaci\u00f3n<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>La investigaci\u00f3n en curso tambi\u00e9n est\u00e1 explorando <a href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/guide-cidp-disease-treatment-options\/\">terapias adicionales<\/a> que podr\u00edan mejorar los resultados para los pacientes con CIDP. A continuaci\u00f3n, se presenta un resumen de los tratamientos m\u00e1s prometedores:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Anticuerpos monoclonales:<\/strong> <a href=\"https:\/\/ameripharmaspecialty.com\/es\/cancer\/rituximab-rituxan\/\">Rituximab<\/a> y <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20049473\/\" target=\"_blank\" rel=\"noreferrer noopener\">alemtuzumab<\/a> muestran resultados prometedores para los casos refractarios y de CIDP mediados por c\u00e9lulas B.<\/li>\n\n\n\n<li><strong>Trasplantes de c\u00e9lulas madre:<\/strong> <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6990890\/\" target=\"_blank\" rel=\"noreferrer noopener\">Trasplante aut\u00f3logo de c\u00e9lulas madre hematopoy\u00e9ticas<\/a> (AHSCT) puede restablecer las respuestas inmunes y conducir a la remisi\u00f3n en formas graves de la enfermedad resistentes al tratamiento.<\/li>\n\n\n\n<li><strong>Terapias inmunol\u00f3gicas dirigidas:<\/strong> <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/cen3.12567\" target=\"_blank\" rel=\"noreferrer noopener\">Anticuerpos antinodales\/paranodales<\/a> Se est\u00e1n investigando variantes m\u00e1s agresivas de CIDP.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-is-there-a-cure-for-cidp-disease\"><span class=\"ez-toc-section\" id=\"Is_There_a_Cure_for_CIDP_Disease\"><\/span>\u00bfExiste una cura para la enfermedad CIDP?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Actualmente, no existen curas definitivas para esta enfermedad. Los tratamientos para la PDIC, como la inmunoglobulina intravenosa (IVIG), la plasmaf\u00e9resis y los corticosteroides, pueden ayudar a controlar los s\u00edntomas e inducir la remisi\u00f3n, pero el control de la enfermedad requiere terapia continua.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-manage-cidp-with-ameripharma-specialty\"><span class=\"ez-toc-section\" id=\"Manage_CIDP_With_AmeriPharma%C2%AE_Specialty\"><\/span>Administre CIDP con la especialidad AmeriPharma\u00ae<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Los avances en la comprensi\u00f3n de la inmunopatolog\u00eda de la polineuropat\u00eda desmielinizante inflamatoria cr\u00f3nica (CIDP) han dado lugar a nuevos tratamientos. Si bien las terapias actuales, como los corticosteroides, la inmunoglobulina intravenosa (IVIG) y la plasmaf\u00e9resis, siguen siendo fundamentales, las terapias emergentes, incluidos los anticuerpos monoclonales y otros tratamientos inmunol\u00f3gicos dirigidos, podr\u00edan ofrecer opciones de tratamiento m\u00e1s precisas y eficaces en el futuro.<\/p>\n\n\n\n<p>Lo crucial es diagnosticar la enfermedad a tiempo y recibir tratamientos personalizados para la PDIC. Si usted o un ser querido padece esta afecci\u00f3n, <a href=\"https:\/\/ameripharmaspecialty.com\/es\/about-us\/\">Farmacia especializada AmeriPharma\u00ae<\/a> puede ayudar<\/p>\n\n\n\n<p>Nuestro acreditado URAC <a href=\"https:\/\/ameripharmaspecialty.com\/es\/\">farmacia especializada<\/a> Ofrece medicamentos para la CIDP dif\u00edciles de encontrar y tratamientos de infusi\u00f3n en el hogar en m\u00e1s de 40 estados y territorios de EE. UU.<\/p>\n\n\n\n<p><a href=\"https:\/\/ameripharmaspecialty.com\/es\/book-a-call\/\">Reservar una llamada<\/a> con nosotros hoy para hablar con un navegador de pacientes y comenzar a recibir atenci\u00f3n especializada con coordinaci\u00f3n de servicios completos, <a href=\"https:\/\/ameripharmaspecialty.com\/es\/financial-assistance\/\">asistencia para copagos<\/a>y soporte 24\/7\/365.<\/p>","protected":false},"excerpt":{"rendered":"<p>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder affecting approximately 5 to 7 people per 100,000 worldwide. Although it can lead to progressive nerve damage and disability, several therapies can help control symptoms, reduce inflammation, and slow disease progression.<\/p>","protected":false},"author":7,"featured_media":27759,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[5],"tags":[8],"class_list":["post-27760","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cidp","tag-dr-christine-leduc"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Your Guide to Current and Emerging Treatments for CIDP<\/title>\n<meta name=\"description\" content=\"Learn about the most effective CIDP treatments. Explore conventional CIDP medications and new CIDP treatments that are showing promise in clinical trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Your Guide to Current and Emerging Treatments for CIDP\" \/>\n<meta property=\"og:description\" content=\"Learn about the most effective CIDP treatments. Explore conventional CIDP medications and new CIDP treatments that are showing promise in clinical trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-17T17:06:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-16T22:02:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Christine Leduc, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Christine Leduc, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cidp\\\/cidp-treatment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cidp\\\/cidp-treatment\\\/\"},\"author\":{\"name\":\"Dr. Christine Leduc, PharmD\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/0d161a7a3c2b0cf54ab0cf25c936dd87\"},\"headline\":\"Your Guide to Current and Emerging Treatments for CIDP\",\"datePublished\":\"2022-06-17T17:06:32+00:00\",\"dateModified\":\"2026-04-16T22:02:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cidp\\\/cidp-treatment\\\/\"},\"wordCount\":1128,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cidp\\\/cidp-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/ivig-cidp-treatments.jpg\",\"keywords\":[\"Dr. Christine Leduc\"],\"articleSection\":[\"CIDP\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cidp\\\/cidp-treatment\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cidp\\\/cidp-treatment\\\/\",\"name\":\"Your Guide to Current and Emerging Treatments for CIDP\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cidp\\\/cidp-treatment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cidp\\\/cidp-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/ivig-cidp-treatments.jpg\",\"datePublished\":\"2022-06-17T17:06:32+00:00\",\"dateModified\":\"2026-04-16T22:02:48+00:00\",\"description\":\"Learn about the most effective CIDP treatments. Explore conventional CIDP medications and new CIDP treatments that are showing promise in clinical trials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cidp\\\/cidp-treatment\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/cidp\\\/cidp-treatment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cidp\\\/cidp-treatment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/ivig-cidp-treatments.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/ivig-cidp-treatments.jpg\",\"width\":1280,\"height\":853},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/cidp\\\/cidp-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Your Guide to Current and Emerging Treatments for CIDP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/0d161a7a3c2b0cf54ab0cf25c936dd87\",\"name\":\"Dr. Christine Leduc, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g\",\"caption\":\"Dr. Christine Leduc, PharmD\"},\"description\":\"Dr. Christine Leduc, PharmD, was born and raised in Irvine, CA. She attended college at Midwestern University, where she graduated cum laude. The most rewarding part of her job is suggesting lifestyle changes, educating patients on how their medication works, and precepting future pharmacists. Her areas of expertise are customer service and knowledge of specialty medication. Having worked in the service industry in the past, she has gained the customer service skills necessary to understand the needs of her patients. Dr. Leduc is currently precepting students from Marshall B. Ketchum University, University of Kansas, and Midwestern University. In her free time, she enjoys traveling, baking, and gardening. See Author Biography\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/christine-leduc\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Su gu\u00eda sobre tratamientos actuales y emergentes para la CIDP","description":"Inf\u00f3rmese sobre los tratamientos m\u00e1s eficaces para la PDIC. Explore los medicamentos convencionales para la PDIC y los nuevos tratamientos prometedores en ensayos cl\u00ednicos.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-treatment\/","og_locale":"es_MX","og_type":"article","og_title":"Your Guide to Current and Emerging Treatments for CIDP","og_description":"Learn about the most effective CIDP treatments. Explore conventional CIDP medications and new CIDP treatments that are showing promise in clinical trials.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-treatment\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2022-06-17T17:06:32+00:00","article_modified_time":"2026-04-16T22:02:48+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments.jpg","type":"image\/jpeg"}],"author":"Dr. Christine Leduc, PharmD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Christine Leduc, PharmD","Est. reading time":"6 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/cidp\/cidp-treatment\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/cidp\/cidp-treatment\/"},"author":{"name":"Dr. Christine Leduc, PharmD","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/0d161a7a3c2b0cf54ab0cf25c936dd87"},"headline":"Your Guide to Current and Emerging Treatments for CIDP","datePublished":"2022-06-17T17:06:32+00:00","dateModified":"2026-04-16T22:02:48+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/cidp\/cidp-treatment\/"},"wordCount":1128,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/cidp\/cidp-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments.jpg","keywords":["Dr. Christine Leduc"],"articleSection":["CIDP"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/cidp\/cidp-treatment\/","url":"https:\/\/ameripharmaspecialty.com\/cidp\/cidp-treatment\/","name":"Su gu\u00eda sobre tratamientos actuales y emergentes para la CIDP","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/cidp\/cidp-treatment\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/cidp\/cidp-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments.jpg","datePublished":"2022-06-17T17:06:32+00:00","dateModified":"2026-04-16T22:02:48+00:00","description":"Inf\u00f3rmese sobre los tratamientos m\u00e1s eficaces para la PDIC. Explore los medicamentos convencionales para la PDIC y los nuevos tratamientos prometedores en ensayos cl\u00ednicos.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/cidp\/cidp-treatment\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/cidp\/cidp-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/cidp\/cidp-treatment\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments.jpg","width":1280,"height":853},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/cidp\/cidp-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/"},{"@type":"ListItem","position":2,"name":"Your Guide to Current and Emerging Treatments for CIDP"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/#website","url":"https:\/\/ameripharmaspecialty.com\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/0d161a7a3c2b0cf54ab0cf25c936dd87","name":"Dra. Christine Leduc, PharmD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f2e7e868ac19420a5672d88350e7e0e3c6a750140410fd606eec96984812e89?s=96&d=mm&r=g","caption":"Dr. Christine Leduc, PharmD"},"description":"La Dra. Christine Leduc, doctora en farmacia, naci\u00f3 y creci\u00f3 en Irvine, California. Curs\u00f3 estudios universitarios en la Universidad Midwestern, donde se gradu\u00f3 con honores. Lo m\u00e1s gratificante de su trabajo es sugerir cambios en el estilo de vida, educar a los pacientes sobre el funcionamiento de sus medicamentos y ser tutora de futuros farmac\u00e9uticos. Sus \u00e1reas de especializaci\u00f3n son la atenci\u00f3n al cliente y el conocimiento de medicamentos especializados. Tras haber trabajado en el sector servicios, ha adquirido las habilidades de atenci\u00f3n al cliente necesarias para comprender las necesidades de sus pacientes. Actualmente, la Dra. Leduc imparte clases a estudiantes de la Universidad Marshall B. Ketchum, la Universidad de Kansas y la Universidad Midwestern. En su tiempo libre, disfruta de viajar, la reposter\u00eda y la jardiner\u00eda. Ver biograf\u00eda de la autora.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/christine-leduc\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-18x12.jpg",18,12,true],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Christine Leduc, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/christine-leduc\/"},"uagb_comment_info":0,"uagb_excerpt":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder affecting approximately 5 to 7 people per 100,000 worldwide. Although it can lead to progressive nerve damage and disability, several therapies can help control symptoms, reduce inflammation, and slow disease progression.","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-18x12.jpg",18,12,true],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/08\/ivig-cidp-treatments.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Christine Leduc, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/christine-leduc\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/cidp\/\" rel=\"category tag\">CIDP<\/a>","rttpg_excerpt":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder affecting approximately 5 to 7 people per 100,000 worldwide. Although it can lead to progressive nerve damage and disability, several therapies can help control symptoms, reduce inflammation, and slow disease progression.","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/27760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=27760"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/27760\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/27759"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=27760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=27760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=27760"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}